(IN BRIEF) Sanofi has secured regulatory approval in China for two innovative medicines, Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome. The approvals expand treatment options for patients with serious cardiovascular and rare metabolic diseases and underscore … Read the full press release →
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged aficamten, cardiovascular disease, China NMPA, clinical phase 3 trials, familial chylomicronemia syndrome, FCS, Greater China, innovative medicines, Myqorzo, obstructive hypertrophic cardiomyopathy, oHCM, Olivier Charmeil, plozasiran, rare diseases, Redemplo, Sanofi, Sanofi Strengthens China Portfolio with Approval of Two Innovative Therapies for oHCM and FCS, siRNA therapy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
